Triana Biomedicines Taps Dr. Mohan Bala as Chief Operating Officer

Triana Biomedicines Inc., a biopharmaceutical company focused on advancing a target-first and proximity-first molecular glue discovery platform to address difficult to drug disease targets, has appointed Dr. Mohan Bala as Chief Operating Officer (COO).

Bala brings more than 30 years of industry experience in program leadership, program development, market access, product strategy, and business development to Triana. His expertise spans the full development continuum, from early to late-stage programs, across both small biotech and large pharmaceutical organizations.

Prior to joining Triana, he served as Chief Development Officer at Mersana Therapeutics, where he played a key role in business development efforts that culminated in the company’s acquisition by Day One Biopharmaceuticals. Before that, he was Chief Operating Officer at Constellation Pharmaceuticals, where he led multiple development functions, while also contributing significantly to the business activities that led to the company’s acquisition by MorphoSys. Earlier in his career, Bala held roles of increasing responsibility at TESARO, Sanofi, GlaxoSmithKline, Centocor, and Research Triangle Institute. He holds a PhD in Management Science from the University of Chicago.

“I’m excited to join Triana at this stage of its development. I was attracted by the Company’s molecular glue technology, the experience and vision of the leadership team, and the opportunity to advance a pipeline focused on patients with significant unmet needs,” said Bala. “I am particularly encouraged by the potential of TRI-611 for ALK+ NSCLC and look forward to working with the team as Triana continues to advance more of its pipeline programs into the clinic.”